Kevzara was tested on critically ill coronavirus patients. Photo: Robert Nickelsberg/Getty Images

Regeneron Pharmaceuticals and Sanofi have shut down the late-stage clinical trial that was testing whether their existing arthritis drug, Kevzara, could improve the condition of COVID-19 patients who were on ventilators.

The bottom line: Kevzara fared no better than a placebo, as it failed to help COVID-19 patients recover or prevent death. Remdesivir remains as the only treatment that has shown any kind of benefit for sick coronavirus patients, although dexamethasone appears to hold the most promise.

Go deeper

23 hours ago - Health

Nurses rally nationwide to demand protection amid pandemic

Healthcare workers on their way to work walk past demonstrators taking part in a national day of action in Miami on Wednesday. Photo: Joe Raedle/Getty Images

Nurses took more than 200 active demonstrations inside and outside U.S. hospital facilities in at least 16 states and the District of Columbia on Wednesday to demand full personal protective equipment and federal government action.

Driving the news: National Nurses United (NNU) members are demanding that the Senate pass the HEROES Act, House Democrats' $3 trillion pandemic recovery package, which they said would protect health care workers by ensuring domestic production of PPE through the Defense Production Act.

Updated 23 hours ago - Technology

Facebook, Twitter take down Trump post saying kids are immune to coronavirus

Photo: NurPhoto/Getty Images

Facebook removed a video post from President Trump Wednesday in which he claimed in an interview with Fox News that children are "almost immune" to COVID-19.

Why it matters: It’s the first time that Facebook has removed content from Trump's account for violating policies on coronavirus-related misinformation.

Coronavirus hotspots begin to improve

Data: The COVID Tracking Project, state health departments; Map: Andrew Witherspoon, Danielle Alberti, Sara Wise/Axios

Coronavirus infections are falling or holding steady in most of the country, including the hard-hit hotspots of Arizona, California and Florida.

The big picture: A decline in new infections is always good news, but don't be fooled: the U.S. still has a very long way to go to recover from this summer's surge.